BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27553679)

  • 1. High Frequency of Bone Marrow Involvement in Intravascular Large B-Cell Lymphoma.
    Wang J; Ding W; Gao L; Yao W; Chen M; Zhao S; Liu W; Zhang W
    Int J Surg Pathol; 2017 Apr; 25(2):118-126. PubMed ID: 27553679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
    Zou D; Yi S; Cui R; Liu W; Li C; Zhong S; Yu Z; Li Z; Lv R; Ru K; Wang H; An G; Xu Y; Qiu L
    BMC Med Genet; 2017 Feb; 18(1):16. PubMed ID: 28209136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review.
    Li Q; Li J; Yang K; Peng Y; Xiang Y; Sun S; Zeng J; Zhang X; Wang J
    Diagn Pathol; 2020 Jun; 15(1):72. PubMed ID: 32513269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China.
    Zhang J; Sun J; Feng J; Luo Y; Ling Q; Wu S; Zeng X; Liang Z
    Virchows Arch; 2018 Jul; 473(1):95-103. PubMed ID: 29802470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.
    Boonsakan P; Iamsumang W; Chantrathammachart P; Chayavichitsilp P; Suchonwanit P; Rutnin S
    Biomed Res Int; 2020; 2020():1350820. PubMed ID: 32566654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
    Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
    Murase T; Yamaguchi M; Suzuki R; Okamoto M; Sato Y; Tamaru J; Kojima M; Miura I; Mori N; Yoshino T; Nakamura S
    Blood; 2007 Jan; 109(2):478-85. PubMed ID: 16985183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
    Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
    Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
    Shen X; Zhou LT; Li AQ; Yi HM; Ouyang BS; Xu HM; Xie JL; Gu YJ; Zhang L; Dong L
    Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):120-125. PubMed ID: 35152630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.